The stock of Taysha Gene Therapies Inc. (NASDAQ:TSHA) increased by $0.64 on Friday to finish at $1.38, up 86.59 percent. The last five days have seen an average of 14,174,752 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$0.8200. The average number of shares traded over the last 20 days was 3,662,203, while the average volume over the last 50 days totaled 1,634,905.
TSHA stock appreciated 99.55% since last month. On 07/27/23, the company’s shares reached a one-month low of $0.6200. The stock touched a high of $4.63 on 01/17/23, after rallying from a low of $0.50 in 52 weeks. The price of TSHA stock has declined by -38.99% or -$0.8200 this year, reaching a new high 2 times. Still, the stock price is down -70.22% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TSHA stock investors should be aware that Taysha Gene Therapies Inc. (TSHA) stock had its last reported insider trading activity 32 days ago on Jul 13. On Jul 13, 10% Owner Session R.A. II sold 5,344 shares at $0.70 each. This transaction resulted in the insider making $3,741. On Jul 12, Session R.A. II sold 80,528 shares at a price of US$0.71. After the transaction, the insider now owns 8,877,091 shares. 10% Owner Session R.A. II had earlier sold 18,100 shares on Jun 23 for $0.70 a share. The transaction was completed for $12,735.
Financial Health
For the three months ended March 30, Taysha Gene Therapies Inc.’s quick ratio was 1.30, while its current ratio was 1.30, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $164.95 million and revenue of $2.5 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TSHA’s return on assets (ROA) during the last 12 months has been -110.90%. There was a -417.60% return on investment (ROI) in the past year.
Earnings Surprise
According to Taysha Gene Therapies Inc.’s quarterly financial report for the quarter that ended March 30. Net income for the quarter came in at $4.71 million, while revenues rose by 100.0% to $2.5 million. It was predicted that Taysha Gene Therapies Inc.’s quarterly earnings would be -$0.28, but it ended up being -$0.35. EBITDA was -$16.23 million for the quarter. At the end of Taysha Gene Therapies Inc.’s most recent quarter ended March 30, its liabilities totaled 116.55 million, while its total debt was $60.85 million. Equity owned by shareholders amounts to $64.18 million.
Technical Picture
Here’s a quick look at Taysha Gene Therapies Inc.’s (TSHA) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 91.99%, suggesting the stock is Overbought, with a 323.76% historical volatility rate.
The stochastic %K and %D were 65.88% and 67.24% respectively, while the average true range (ATR) was 0.1669. Based on the 14-day stochastic reading of 68.91%, the RSI (14) reading is 87.67%. On the 9-day MACD Oscillator, the stock is at 0.1644, and the 14-day reading is at 0.2129.
Analyst Ratings
Taysha Gene Therapies Inc. (NASDAQ: TSHA) was downgraded by Jefferies to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Taysha Gene Therapies Inc. (TSHA) an Buy rating. TSHA is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 7 others recommend it as a buy.
What is TSHA’s price target for the next 12 months?
The current consensus forecast for the stock is between $0.70 and $13.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for Taysha Gene Therapies Inc. (TSHA) is $5.13.
